سعر فاتروكسيم 550مجم 30 قرص 2024

Rifaximin 550 mg film-coated tablets (ATM Pharmaceutical Industries / EGPI), pack of 30 (3 strips x 10).

• Reduction in risk of overt hepatic encephalopathy recurrence in adults.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Hepatic encephalopathy trials (≥10% with rifaximin 550 mg twice daily): peripheral edema (15%), nausea (14%), dizziness (13%), fatigue (12%) and ascites (11%); muscle spasms, pruritus, abdominal pain, anemia, depression and others also reported.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• IBS-D trials: most common adverse reactions ALT increased (2%) and nausea (2%). Postmarketing: hypersensitivity reactions (exfoliative dermatitis, rash, angioneurotic edema, urticaria, flushing, pruritus, anaphylaxis); severe cutaneous adverse reactions (SJS/TEN); rhabdomyolysis in patients with cirrhosis.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to rifaximin, any rifamycin antimicrobial agent, or any component of the product.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Travelers' diarrhea not caused by E. coli: not effective in diarrhea complicated by fever and/or blood in the stool or due to pathogens other than E. coli; discontinue if symptoms worsen or persist more than 24–48 hours.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Clostridioides difficile-associated diarrhea has been reported and may range from mild diarrhea to fatal colitis; evaluate if diarrhea occurs.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Prescribing in the absence of a proven or strongly suspected bacterial infection is unlikely to help and increases the risk of drug-resistant bacteria.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• P-glycoprotein inhibitors (e.g., cyclosporine)Concomitant cyclosporine markedly increased rifaximin systemic exposure; caution with P-gp inhibitors.DailyMed (U.S. National Library of Medicine)
• WarfarinChanges in INR (increase or decrease) reported with concomitant use; monitor INR and prothrombin time and adjust warfarin dose as needed.DailyMed (U.S. National Library of Medicine)

• No available human data on rifaximin in pregnancy; in animal studies rifaximin was teratogenic in rats and rabbits at exposures above human exposure. Advise pregnant women of the potential risk to a fetus.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• No information on the presence of rifaximin in human milk, effects on the breastfed infant or milk production.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Rifaximin: Binds the beta-subunit of bacterial DNA-dependent RNA polymerase, inhibiting bacterial RNA synthesis; minimally absorbed after oral use and acts locally in the gut.